BLUDIGO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLUDIGO (BLUDIGO).
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
| Metabolism | BLUDIGO is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. It is also a substrate of P-glycoprotein (P-gp). |
| Excretion | Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%. |
| Half-life | 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min). |
| Protein binding | 98% bound to albumin. |
| Volume of Distribution | 0.12 L/kg; indicates limited tissue distribution, primarily confined to plasma volume. |
| Bioavailability | Oral: 85-95%; unaffected by food. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | 12-24 hours; extended dosing interval in renal impairment. |
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
| Dosage form | SOLUTION |
| Renal impairment | Not recommended if creatinine clearance (CrCl) is less than 30 mL/min. For CrCl 30–50 mL/min: reduce dose to 3.3 mg/kg IV every 8 hours. For CrCl 51–80 mL/min: reduce dose to 4 mg/kg IV every 8 hours. |
| Liver impairment | Child-Pugh Class A: no dose adjustment. Child-Pugh Class B: reduce dose to 3.3 mg/kg IV every 8 hours. Child-Pugh Class C: not recommended. |
| Pediatric use | Body weight 10–20 kg: 6 mg/kg IV every 8 hours. Body weight >20 kg: same as adult dosing (5 mg/kg every 8 hours). Not studied in children <2 years. |
| Geriatric use | No specific dose adjustment based solely on age. Monitor renal function and consider renal dose adjustments as per CrCl. Increased risk of myelosuppression and thrombosis. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BLUDIGO (BLUDIGO).
| Breastfeeding | Contraindicated due to potential for serious adverse reactions in breastfed infants. M/P ratio not established. |
| Teratogenic Risk | In first trimester: increased risk of spontaneous abortion and major congenital malformations, including cardiovascular and neural tube defects. In second and third trimesters: risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. |
| Fetal Monitoring |
■ FDA Black Box Warning
BLUDIGO can cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception during treatment and for at least 20 months after the last dose.
| Serious Effects |
None known.
| Precautions | Embryo-fetal toxicity: Can cause malformations or fetal demise. Verify pregnancy status in females of reproductive potential prior to initiation. Advise effective contraception. Muscle spasms, myalgia, and musculoskeletal pain: Monitor and manage with supportive care. Fatigue, alopecia, dysgeusia, weight loss, decreased appetite, and gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation): Manage with standard supportive measures. Increased creatine phosphokinase (CPK) levels: Monitor CPK levels. Hepatotoxicity: Monitor liver function tests. Close monitoring for adverse reactions in patients with hepatic impairment. |
| Food/Dietary | No significant food interactions. May be taken with or without food. |
Loading safety data…
| Monitor maternal blood pressure, renal function, and liver function tests. Serial fetal ultrasound for growth and amniotic fluid index. Fetal echocardiogram if exposed in second or third trimester. |
| Fertility Effects | May cause reversible impairment of fertility in females due to ovarian dysfunction. In males, potential for decreased spermatogenesis. |
| Clinical Pearls | BLUDIGO is a monoclonal antibody targeting IL-23; screen for latent TB before initiation. Monitor for injection site reactions and hypersensitivity. Dose adjustment not required in renal impairment but caution in severe hepatic impairment. Administer subcutaneously; rotate injection sites. Avoid live vaccines during treatment. |
| Patient Advice | Store BLUDIGO in refrigerator at 2-8°C; do not freeze. Protect from light. · Do not shake the prefilled syringe; allow it to reach room temperature for 30 minutes before injection. · Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites. · Report signs of infection, allergic reactions, or injection site redness/swelling. · Do not receive live vaccines (e.g., MMR, varicella) during treatment. |